Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

…, SS Buys, A Osorio, C Engel, K Kast, RK Schmutzler… - Jama, 2017 - jamanetwork.com
Importance The clinical management ofBRCA1andBRCA2mutation carriers requires accurate,
prospective cancer risk estimates. Objectives To estimate age-specific risks of breast, …

Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

…, M Friedlander, B Arun, N Loman, RK Schmutzler… - The Lancet, 2010 - thelancet.com
Background Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor,
induced synthetic lethality in BRCA-deficient cells. A maximum tolerated dose and initial …

[HTML][HTML] Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

…, R Shapira-Frommer, RK Schmutzler… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
… Domchek, Clovis Oncology (C) Stock Ownership: Karin Bowen, AstraZeneca; Anitra
Fielding, AstraZeneca Honoraria: Rita K. Schmutzler, AstraZeneca Research Funding: Bella …

Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

…, JN Weitzel, A Oaknin, N Loman, K Lu, RK Schmutzler… - The lancet, 2010 - thelancet.com
Background Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor
that induces synthetic lethality in homozygous BRCA-deficient cells. We aimed to assess …

Large-scale genotyping identifies 41 new loci associated with breast cancer risk

…, N Dahmen, L Beckman, A Meindl, RK Schmutzler… - Nature …, 2013 - nature.com
Breast cancer is the most common cancer among women. Common variants at 27 loci have
been identified as associated with susceptibility to breast cancer, and these account for ∼9…

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

…, M Kiechle, CG Mathew, D Schindler, RK Schmutzler… - Nature …, 2010 - nature.com
Germline mutations in a number of genes involved in the recombinational repair of DNA
double-strand breaks are associated with predisposition to breast and ovarian cancer. RAD51C …

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 …

…, JE Weaver, AK Godwin, RK Schmutzler… - … Biomarkers & Prevention, 2012 - AACR
Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors
differ in their pathology. Analysis of larger datasets of mutation carriers should allow further …

Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results

CK Kuhl, RK Schmutzler, CC Leutner, A Kempe… - Radiology, 2000 - pubs.rsna.org
PURPOSE: To compare magnetic resonance (MR) imaging with conventional imaging in
screening high-risk women. MATERIALS AND METHODS: This prospective trial included 192 …

Prediction of breast cancer risk based on profiling with common genetic variants

…, Z Takhirova, A Meindl, RK Schmutzler… - Journal of the …, 2015 - academic.oup.com
Background: Data for multiple common susceptibility alleles for breast cancer may be combined
to identify women at different levels of breast cancer risk. Such stratification could guide …

Newly discovered breast cancer susceptibility loci on 3p24 and 17q23. 2

…, A González-Neira, J Benitez, RK Schmutzler… - Nature …, 2009 - nature.com
Genome-wide association studies (GWAS) have identified seven breast cancer susceptibility
loci, but these explain only a small fraction of the familial risk of the disease. Five of these …